Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Olga Schuth

Plastic Surgery Rapid City, SD Medical Doctor

NPI 1427403294 CMS profile 8806290

353 Fairmont Blvd, Box 980154, Rapid City, SD 57701

Open in the dashboard

General payments

$2,193

37 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Olga Schuth of Rapid City, SD is reported in the CMS Open Payments database as having received $2,193 across 37 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $724 12
2024 General $343 12
2023 General $796 7
2022 General $126 1
2021 General $190 4
2020 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Olga Schuth
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Olga Schuth were reported at $724. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Olga Schuth Plastic Surgery median Middle half National median
2019 $0 $371 $122–$1,483 $163
2020 $14 $158 $52–$438 $114
2021 $190 $249 $87–$752 $132
2022 $126 $274 $102–$793 $149
2023 $796 $299 $113–$891 $160
2024 $343 $361 $124–$1,062 $164
2025 $724 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Integra LifeSciences Corporation $735 11 payments
  2. Stryker Corporation $545 1 payment
  3. PolyNovo North America LLC $226 5 payments
  4. Smith+Nephew, Inc. $142 5 payments
  5. Sonex Health, Inc. $126 1 payment
  6. Sioux Surgical Inc $111 2 payments
  7. Avita Medical Americas, LLC $94 4 payments
  8. AxoGen $67 1 payment
  9. Organogenesis Inc. $30 1 payment
  10. Mentor Worldwide LLC $29 1 payment
  11. Other $87 5 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $1,025 31 payments
  2. Travel and Lodging $671 2 payments
  3. Long term medical supply or device loan $497 4 payments
Products named General payments · program years 2020–2025
  1. 1688 $545 1 payment
  2. MICROMATRIX $409 3 payments
  3. INTEGRA DERMAL REGENERATION TEMPLATE $238 7 payments
  4. PRIMATRIX $238 7 payments
  5. INTEGRA WOUND MATRIX (THIN) $190 4 payments
  6. INTEGRA MESHED BILAYER WOUND MATRIX $190 4 payments
  7. INTEGRA FLOWABLE WOUND MATRIX $190 4 payments
  8. NOVOSORB BTM $132 3 payments
  9. ULTRAGUIDECTR $126 1 payment
  10. ULTRAGUIDETFR $126 1 payment
  11. Other $1,158 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

15

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$224

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

0%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 15 $224

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$95,780

Medicare's payments for the services billed

Medicare patients

204

Average age 70

Services billed

541

135 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 63%
Diabetes 31%
Depression 25%
Osteoporosis 23%
Ischemic heart disease 19%
Atrial fibrillation 18%
Chronic kidney disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

37 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record